StreetInsider.com News Articles

Cocrystal Pharma completes dosing in norovirus Phase 1b trial

Wed, 09 Sep 2026 07:00:28 -0400

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that the last subject has been dosed in its Phase 1b norovirus human challenge study evaluating CDI-988 as both a preventive treatment and therapy for norovirus infections, according to a company statement.

The randomized, double-blind, placebo-controlled study was conducted at Emory University School of Medicine and enrolled healthy subjects between the ages of 18 and 49. Participants were infected with the norovirus GII.2 strain, known as Snow Mountain Virus, and received either oral CDI-988 or a placebo. The primary endpoint is efficacy versus placebo in reducing the incidence of clinical symptoms, with secondary endpoints including

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Wed, 09 Sep 2026 07:00:00 -0400

No serious adverse events reported to date

Preliminary efficacy results expected in late 2026 or early 2027

MIAMI, Fla. And BOTHELL, Wash., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced that the last subject has been dosed in its Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988 as both a preventive and treatment for norovirus infections.

CDI-988 is the first oral antiviral drug candidate

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Wed, 09 Sep 2026 07:00:00 -0400

No serious adverse events reported to date

Preliminary efficacy results expected in late 2026 or early 2027

CDI-988 is the first oral antiviral drug candidate

Form 3 Cocrystal Pharma, Inc. For: Aug 12 Filed by: Brosgart Carol L

Fri, 21 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260821/26961483.html

Form 3 Cocrystal Pharma, Inc. For: Aug 12 Filed by: Brosgart Carol L

Fri, 21 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260821/26961483.html

Form 8-K Cocrystal Pharma, Inc. For: Aug 12

Tue, 18 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260818/26944782.html

Form 8-K Cocrystal Pharma, Inc. For: Aug 12

Tue, 18 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260818/26944782.html

Form 8-K Cocrystal Pharma, Inc. For: Aug 17

Mon, 17 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260817/26938155.html

Form 8-K Cocrystal Pharma, Inc. For: Aug 17

Mon, 17 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260817/26938155.html

Cocrystal Pharma adds Carol Brosgart, MD to its board

Mon, 17 Aug 2026 11:17:12 -0400

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced the appointment of Carol Brosgart, MD to its Board of Directors, effective Aug. 12, 2026, according to a company statement.

Dr. Brosgart has experience in antiviral therapy, epidemiology, and biopharmaceutical consulting. She spent more than a decade at Gilead Sciences, where she contributed to the development and regulatory approval of antiviral therapies Viread and Hepsera. She received her M.D. from the University of California, San Francisco School of Medicine, where she currently serves as a Clinical Professor of Medicine, Biostatistics and Epidemiology.

Dr. Brosgart currently sits on the boards of Galmed Pharmaceuticals, Eradivir Biotech, and Merlin

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Mon, 17 Aug 2026 11:17:00 -0400

BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory.

"Dr. Brosgart holds a distinguished record in antiviral drug development, having contributed to the development and FDA approval of therapies that have benefited patients worldwide,” said Roger Kornberg, Ph.D.,

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Mon, 17 Aug 2026 11:17:00 -0400

Form 10-Q Cocrystal Pharma, Inc. For: Jun 30

Thu, 13 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260813/26916487.html

Form 10-Q Cocrystal Pharma, Inc. For: Jun 30

Thu, 13 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260813/26916487.html

Form SCHEDULE 13D Cocrystal Pharma, Inc. Filed by: OPKO HEALTH, INC.

Fri, 07 Aug 2026 19:50:00 -0400

si-local-file:///var/storage/secattach/20260807/26892511.html

Form SCHEDULE 13D Cocrystal Pharma, Inc. Filed by: OPKO HEALTH, INC.

Fri, 07 Aug 2026 19:50:00 -0400

si-local-file:///var/storage/secattach/20260807/26892511.html

Form SCHEDULE 13D/A Cocrystal Pharma, Inc. Filed by: FROST PHILLIP MD ET AL

Fri, 07 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260807/26892166.html

Form SCHEDULE 13D/A Cocrystal Pharma, Inc. Filed by: FROST PHILLIP MD ET AL

Fri, 07 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260807/26892166.html

Form 4 Cocrystal Pharma, Inc. For: Aug 05 Filed by: FROST PHILLIP MD ET AL

Thu, 06 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26885497.html

Form 4 Cocrystal Pharma, Inc. For: Aug 05 Filed by: FROST PHILLIP MD ET AL

Thu, 06 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26885497.html

Form 4 Cocrystal Pharma, Inc. For: Aug 03 Filed by: FROST PHILLIP MD ET AL

Wed, 05 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26874283.html

Form 4 Cocrystal Pharma, Inc. For: Aug 03 Filed by: FROST PHILLIP MD ET AL

Wed, 05 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26874283.html

Form 8-K Cocrystal Pharma, Inc. For: Jul 31

Mon, 03 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260803/26853840.html

Form 8-K Cocrystal Pharma, Inc. For: Jul 31

Mon, 03 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260803/26853840.html

Opko Health invests $5M in Cocrystal Pharma via private placement

Mon, 03 Aug 2026 07:00:12 -0400

Cocrystal Pharma (NASDAQ: COCP) announced a $5 million private placement with OPKO Health (NASDAQ: OPK), under which OPKO purchased 5,474,053 shares of Cocrystal common stock at $0.9134 per share, based on the Nasdaq Consolidated Bid Price on the trading day of closing. No warrants or other derivative securities were included in the transaction.

The shares were sold as unregistered securities under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. OPKO is described in the press release as a longtime investor in Cocrystal.

James Sapirstein, Chief Executive Officer of Cocrystal Pharma, said the company expects to report topline data from